Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients Aged 4 to 11 Years With Activated Phosphoinositide 3-Kinase Delta Syndrome Followed by an Open-label Long-term Extension

NCT05438407 is registered in ClinicalTrials.gov with Pharming Technologies B.V. as lead sponsor.

NCT NCT05438407
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05438407 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Single Arm Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Leniolisib in Pediatric Patients Aged 4 to 11 Years With Activated Phosphoinositide 3-Kinase Delta Syndrome Followed by an Open-label Long-term Extension
Lead sponsor
Pharming Technologies B.V.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
February 1, 2023
Completion date
December 30, 2026
Enrollment
15 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

apds